Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2013

View Archived Issues

Roche presents highlights of second quarter 2013

Kalydeco beneficial in patients with cystic fibrosis and non-G551D gating mutations

EMA's CHMP issues positive opinion regarding afatinib

FDA lifts clinical hold on Cangene's recombinant factor IX product candidate

FDA grants orphan drug status to Convergence Pharmaceuticals' CNV-1014802

Depomed acquires Lazanda nasal spray

Anacor Pharmaceuticals submits NDA to the FDA for tavaborole

Kolltan in-licenses antibody targeting HER3

AbbVie reports key pipeline events of second quarter 2013

FDA accepts tasimelteon NDA for priority review

Noxxon Pharma patents new nucleic acid molecules

MK-8931 leads to reductions in brain amyloid levels in patients with Alzheimer's disease

Researchers at Nippon Chemiphar present novel P2X4 receptor antagonists

Acetylon Pharmaceuticals and Celgene to advance several HDAC inhibitors

Ref Pharma presents new agents for HCV infection

Scientists at ACEA Biosciences divulge new agents for cancer

Wellcome Trust grants award to GlycoVaxyn for Shigella program

Clinical evaluation of a novel prophylactic therapy for patients with hemophilia B

FDA grants priority review to NDA for MNK-795

U.S. university researchers patent new M1 receptor modulators

Evaluation of a glycoPEGylated recombinant coagulation factor for the treatment of hemophilia

BIND Therapeutics begins dosing in phase II trial in NSCLC

The development of a novel mouse model for Pick's disease

Perrigo enters definitive agreement to acquire Elan

European Commission grants orphan drug designation to BrainStorm's cell therapy for ALS

Novartis receives positive CHMP opinion for Ilaris in systemic juvenile idiopathic arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...